When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie. The company, Tolerance Bio, focuses on preserving the body’s ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...
Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results